THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 1, 2005--Amgen
(Nasdaq:AMGN), the world´s largest biotechnology company, today
announced that it is providing an initial cash contribution of $2.5
million and establishing a company-wide Hurricane Katrina Relief
Program in support of humanitarian aid, with a special focus on access
to health care. A portion of Amgen´s contribution will go to the
American Red Cross for general aid to the region and the balance will
support organizations that can assist in providing access and
continuity of care for patients in the Gulf Coast area, especially
dialysis and oncology patients.
Additionally, the Amgen Foundation will deploy its Disaster Relief
Program Web site for Amgen staff around the globe who wish to
contribute their own funds to the relief and rebuild efforts. The
Amgen Foundation will match all staff contributions via this relief
site. The following organizations are the designated recipients for
contributions made through this program:
American Red Cross - Disaster Relief Fund
America´s Second Harvest
Habitat for Humanity
Baton Rouge Area Foundation´s Hurricane Katrina Displaced
Residents Fund and Hurricane Katrina New Orleans Recovery Fund
"The magnitude of the tragedy in New Orleans and the Gulf states
has been devastating. The Amgen commitment of $2.5 million is intended
to help with the impacted communities´ most critical needs,
particularly health care," said Kevin Sharer, Amgen´s chairman and
chief executive officer.
In keeping with Amgen´s mission to serve patients, the company is
working with suppliers, physicians and customers to ensure
uninterrupted supply of Amgen´s medicines to patients in the Gulf
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science´s promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a broad and deep pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people´s lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
EDITOR´S NOTE: An electronic version of this news release may be
accessed via our Web site at www.amgen.com. Journalists and media
representatives may sign up to receive all news releases
electronically at time of announcement by filling out a short form in
the Media section of the Web site.
CONTACT: Amgen, Thousand Oaks
Mary Klem, 805-447-4587 (Media)
Arvind Sood, 805-447-1060 (Investors)